Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Royalty Pharma plc - SIC # 6794 - PATENT OWNERS AND LESSORS
Ticker
Exchange
SIC #
Website
Latest Ticker
RPRX
Nasdaq
6794
https://www.royaltypharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Royalty Pharma plc
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
- Feb 28th, 2024 9:15 pm
Analysts Have Made A Financial Statement On Royalty Pharma plc's (NASDAQ:RPRX) Yearly Report
- Feb 18th, 2024 12:11 pm
Royalty Pharma Full Year 2023 Earnings: EPS: US$2.54 (vs US$0.098 in FY 2022)
- Feb 17th, 2024 12:09 pm
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
- Feb 16th, 2024 5:04 am
Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis
- Feb 15th, 2024 12:58 pm
Royalty Pharma Reports Q4 and Full Year 2023 Results
- Feb 15th, 2024 12:30 pm
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
- Jan 30th, 2024 9:15 pm
Royalty Pharma (NASDAQ:RPRX) Is Paying Out A Larger Dividend Than Last Year
- Jan 22nd, 2024 10:24 am
Royalty Pharma Announces Dividend Increase
- Jan 19th, 2024 1:15 pm
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2024 12:00 pm
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
- Nov 27th, 2023 9:15 pm
Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%
- Nov 26th, 2023 1:03 pm
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
- Nov 13th, 2023 1:10 pm
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
- Nov 13th, 2023 1:00 pm
The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis
- Nov 9th, 2023 5:15 am
Royalty Pharma Reports Third Quarter 2023 Results
- Nov 8th, 2023 12:00 pm
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
- Oct 19th, 2023 11:59 am
Royalty Pharma Declares Fourth Quarter 2023 Dividend
- Oct 16th, 2023 8:15 pm
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
- Oct 11th, 2023 8:15 pm
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
- Sep 21st, 2023 12:25 pm
Scroll